导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -20.35% | 4400/4773 |
| 近一周 | -2.67% | 2799/5462 |
| 近一月 | -4.20% | 2297/5421 |
| 近一季 | -3.91% | 1497/5209 |
| 近半年 | -14.15% | 3891/4920 |
| 近一年 | -29.61% | 4187/4366 |
| 近两年 | 0.46% | 2884/2954 |
| 近三年 | -14.02% | 2075/2253 |
| 成立以来 | 9.10% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-9.11% 4348/4961 |
-16.15% 4716/5312 |
- - |
- - |
| 2025 | 1.72% 3220/4813 |
10.80% 293/3635 |
-1.02% 3092/4076 |
5.37% 3594/4524 |
-11.98% 4226/4813 |
| 2024 | 19.88% 498/3463 |
2.25% 804/2808 |
-1.30% 1029/3014 |
22.09% 507/3129 |
-2.71% 2165/3463 |
| 2023 | -14.78% 1619/2656 |
3.18% 1248/2280 |
-6.77% 1705/2385 |
-3.63% 963/2515 |
-8.07% 2243/2655 |
| 2022 | -16.92% 533/2207 |
-21.05% 1597/1919 |
19.18% 94/2016 |
-16.21% 1424/2113 |
5.37% 467/2208 |
| 2021 | -11.29% 1108/1822 |
-4.87% 891/1255 |
6.28% 760/1330 |
-13.49% 1345/1466 |
1.42% 938/1822 |
| 2020 | - - |
- - |
- - |
20.72% 50/1164 |
22.00% 49/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 中金中证沪港深优选消费50指数A VS. 长安沪深300非周期A(740101) |